Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Cash & Equivalents: 2016-2025

Historic Cash & Equivalents for Collegium Pharmaceutical (COLL) over the last 10 years, with Sep 2025 value amounting to $150.1 million.

  • Collegium Pharmaceutical's Cash & Equivalents rose 285.26% to $150.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $150.1 million, marking a year-over-year increase of 285.26%. This contributed to the annual value of $70.6 million for FY2024, which is 70.47% down from last year.
  • As of Q3 2025, Collegium Pharmaceutical's Cash & Equivalents stood at $150.1 million, which was up 27.91% from $117.3 million recorded in Q2 2025.
  • Over the past 5 years, Collegium Pharmaceutical's Cash & Equivalents peaked at $283.7 million during Q2 2023, and registered a low of $39.0 million during Q3 2024.
  • Over the past 3 years, Collegium Pharmaceutical's median Cash & Equivalents value was $172.9 million (recorded in 2024), while the average stood at $175.0 million.
  • In the last 5 years, Collegium Pharmaceutical's Cash & Equivalents plummeted by 84.93% in 2024 and then soared by 285.26% in 2025.
  • Collegium Pharmaceutical's Cash & Equivalents (Quarterly) stood at $186.4 million in 2021, then decreased by 6.83% to $173.7 million in 2022, then soared by 37.57% to $238.9 million in 2023, then crashed by 70.47% to $70.6 million in 2024, then spiked by 285.26% to $150.1 million in 2025.
  • Its Cash & Equivalents was $150.1 million in Q3 2025, compared to $117.3 million in Q2 2025 and $96.2 million in Q1 2025.